Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia.
National Research Center "Kurchatov Institute", 123182 Moscow, Russia.
Int J Mol Sci. 2024 Sep 27;25(19):10454. doi: 10.3390/ijms251910454.
Fifty-two years have passed since President Nixon launched the "War on Cancer". Despite unparalleled efforts and funds allocated worldwide, the outlined goals were not achieved because cancer treatment approaches such as chemotherapy, radiation therapy, hormonal and targeted therapies have not fully met the expectations. Based on the recent literature, a new direction in cancer therapy can be proposed which targets connections between cancer cells and their microenvironment by chemical means. Cancer-stromal synapses such as immunological synapses between cancer and immune cells provide an attractive target for this approach. Such synapses form ligand-receptor clusters on the interface of the interacting cells. They share a common property of involving intercellular clusters of spatially proximate and cooperatively acting proteins. Synapses provide the space for the focused intercellular signaling molecules exchange. Thus, the disassembly of cancer-stromal synapses may potentially cause the collapse of various tumors. Additionally, the clustered arrangement of synapse components offers opportunities to enhance treatment safety and precision by using targeted crosslinking chemical agents which may inactivate cancer synapses even in reduced concentrations. Furthermore, attaching a cleavable cell-permeable toxic agent(s) to a crosslinker may further enhance the anti-cancer effect of such therapeutics. The highlighted approach promises to be universal, relatively simple and cost-efficient. We also hope that, unlike chemotherapeutic and immune drugs that interact with a single target, by using supramolecular large clusters that include many different components as a target, the emergence of a resistance characteristic of chemo- and immunotherapy is extremely unlikely.
自尼克松总统发起“抗癌战争”以来,已经过去了 52 年。尽管全世界都做出了无与伦比的努力并投入了大量资金,但仍未实现既定目标,因为化疗、放疗、激素和靶向治疗等癌症治疗方法并未完全满足预期。基于最近的文献,可以提出癌症治疗的新方向,即通过化学手段靶向癌细胞与其微环境之间的连接。癌细胞与免疫细胞之间的免疫突触等癌症-基质突触为这种方法提供了一个有吸引力的靶点。这些突触在相互作用的细胞界面上形成配体-受体簇。它们具有共同的特性,涉及空间邻近且协同作用的细胞内蛋白质簇。突触为聚焦的细胞间信号分子交换提供了空间。因此,癌症-基质突触的解体可能导致各种肿瘤的崩溃。此外,突触成分的聚集排列为使用靶向交联化学剂提供了增强治疗安全性和精确性的机会,即使在较低浓度下,这些化学剂也可能使癌细胞突触失活。此外,将可切割的细胞通透性毒性剂(s)附着到交联剂上可能会进一步增强此类治疗药物的抗癌效果。所强调的方法有望具有普遍性、相对简单和成本效益高。我们还希望,与作用于单个靶标的化学疗法和免疫药物不同,通过使用包含许多不同成分的超分子大簇作为靶标,不太可能出现化学疗法和免疫疗法所具有的耐药特征。